Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

About Adamas Pharmaceuticals

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. Its ADS-5102 is an extended-release version of amantadine that is intended for once daily administration at bedtime. It is developing ADS-8704, which is a fixed-dose combination of its controlled release version of memantine and donepezil for the treatment of moderate to severe dementia related to Alzheimer's disease. Its ADS 8902, a triple combination antiviral drug therapy for influenza. It also offers Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules (formerly MDX-8704) and Namenda XR (memantine hydrochloride) extended release capsules.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADMS
  • CUSIP:
Key Metrics:
  • Previous Close: $13.11
  • 50 Day Moving Average: $14.51
  • 200 Day Moving Average: $15.29
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.34
  • P/E Growth: -0.05
  • Market Cap: $287.49M
  • Outstanding Shares: 21,929,000
  • Beta: 0.54
Additional Links:
Companies Related to Adamas Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Adamas Pharmaceuticals (NASDAQ:ADMS) (?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.00 (144.09% upside)

Analysts' Ratings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Show:
DateFirmActionRatingPrice TargetDetails
7/25/2016Credit Suisse Group AGReiterated RatingBuy$21.00View Rating Details
7/22/2016Noble FinancialReiterated RatingBuy$25.00View Rating Details
7/20/2016Needham & Company LLCReiterated RatingBuy$38.00View Rating Details
6/23/2016MizuhoReiterated RatingBuyView Rating Details
6/15/2016JMP SecuritiesReiterated RatingBuyView Rating Details
6/14/2016Piper Jaffray Cos.Reiterated RatingOverweight$44.00View Rating Details
5/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details
1/26/2016AegisReiterated RatingBuyView Rating Details
9/11/2015William BlairReiterated RatingOutperform$35.00View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
5/10/2016Q1($0.76)($0.65)ViewN/AView Earnings Details
2/23/2016Q4($0.81)($0.58)ViewN/AView Earnings Details
8/11/2015Q215($0.72)($0.78)ViewN/AView Earnings Details
5/13/2015Q414($0.74)($0.69)ViewN/AView Earnings Details
3/3/2015$0.64$0.50ViewN/AView Earnings Details
11/4/2014Q314($0.44)($0.57)ViewN/AView Earnings Details
8/7/2014Q214$0.81$0.88$18.75 million$25.15 millionViewN/AView Earnings Details
5/13/2014Q114($0.09)($0.67)$30.60 million$0.18 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)
Current Year EPS Consensus Estimate: $-3.16 EPS
Next Year EPS Consensus Estimate: $-3.02 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.61)($0.61)($0.61)
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.88)($0.88)($0.88)
Q4 20161($0.90)($0.90)($0.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.00View SEC Filing  
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.00View SEC Filing  
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.00View SEC Filing  
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.00View SEC Filing  
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateHeadline
investornewswire.com logoWill Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Hit $45 Price Target? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - August 19 at 3:34 PM
investornewswire.com logoWill Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Surprise This Quarter? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - August 16 at 8:38 PM
finance.yahoo.com logoADAMAS PHARMACEUTICALS INC Financials (NASDAQ:ADMS)
finance.yahoo.com - August 13 at 3:18 PM
capitalcube.com logoETF’s with exposure to Adamas Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:ADMS)
www.capitalcube.com - August 12 at 3:19 PM
capitalcube.com logoAdamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:ADMS)
www.capitalcube.com - August 11 at 12:30 PM
ftsenews.co.uk logoAdamas Pharmaceuticals, Inc. (ADMS) Updated Price Targets ... - FTSE News (NASDAQ:ADMS)
www.ftsenews.co.uk - August 9 at 12:03 PM
twst.com logoAdamas Pharmaceuticals Inc.: Adamas Reports Second Quarter 2016 Financial Results (NASDAQ:ADMS)
www.twst.com - August 4 at 9:01 PM
sg.finance.yahoo.com logoAdamas reports 2Q loss (NASDAQ:ADMS)
sg.finance.yahoo.com - August 4 at 9:01 PM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) Jumps 5.15% on July 29 - Equities.com (NASDAQ:ADMS)
www.equities.com - July 30 at 3:24 PM
investornewswire.com logoCan Shares Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Hit $45? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - July 29 at 3:19 PM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) Drops 6.32% on July 25 - Equities.com (NASDAQ:ADMS)
www.equities.com - July 27 at 11:58 AM
capitalcube.com logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : July 25, 2016 (NASDAQ:ADMS)
www.capitalcube.com - July 25 at 8:21 AM
News IconStock Displaying Signs of a Downtrend: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Press Telegraph (NASDAQ:ADMS)
presstelegraph.com - July 23 at 3:18 PM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) is Trading Higher on Unusual Volume for July 21 - Equities.com (NASDAQ:ADMS)
www.equities.com - July 23 at 3:18 PM
investornewswire.com logoIs $45 Price Target Attainable For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - July 22 at 3:17 PM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) Jumps 9.66% on July 21 - Equities.com (NASDAQ:ADMS)
www.equities.com - July 21 at 8:53 PM
News IconStock Soars, Rewards Investors Nicely Today: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Engelwood Daily (NASDAQ:ADMS)
www.engelwooddaily.com - July 21 at 3:18 PM
News IconStock Marching Up in Session: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - TGP (NASDAQ:ADMS)
telanaganapress.com - July 21 at 3:18 PM
marketexclusive.com logoBiotech Movers: Adamas Pharmaceuticals Inc (NASDAQ:ADMS), Relypsa Inc (NASDAQ:RLYP) and Biogen Inc ... - Market Exclusive (NASDAQ:ADMS)
marketexclusive.com - July 21 at 3:18 PM
News IconAdamas Pharmaceuticals Inc (NASDAQ:ADMS)'s Company Shares Decreased 10.89% After Low Volatility - Consumer Eagle (NASDAQ:ADMS)
www.consumereagle.com - July 21 at 3:18 PM
fiscalstandard.com logoBroker Outlook For Adamas Pharmaceuticals, Inc. (ADMS) - Fiscal Standard (NASDAQ:ADMS)
www.fiscalstandard.com - July 21 at 11:47 AM
capitalcube.com logoAdamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : July 19, 2016 (NASDAQ:ADMS)
www.capitalcube.com - July 19 at 2:26 PM
News IconAdamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Short Interest Increased By 12.91% - Press Telegraph (NASDAQ:ADMS)
presstelegraph.com - July 19 at 9:30 AM
streetinsider.com logoAllergan (AGN), Adamas Pharma (ADMS) Announce Expanded NAMZARIC Indication - StreetInsider.com (NASDAQ:ADMS)
www.streetinsider.com - July 19 at 9:30 AM
News IconShares Moving Down on the Week: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Engelwood Daily (NASDAQ:ADMS)
www.engelwooddaily.com - July 17 at 8:04 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Adamas Pharmaceuticals, Inc. (ADMS) - Fiscal Standard (NASDAQ:ADMS)
www.fiscalstandard.com - July 17 at 8:04 AM
News IconGreat Point Partners LLC Increased Adamas Pharmaceuticals INC (NASDAQ:ADMS) by $9.40 Million as Shares ... - Consumer Eagle (NASDAQ:ADMS)
www.consumereagle.com - July 16 at 3:18 PM
investornewswire.com logoStrong Sell Calls For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 0 - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - July 16 at 3:18 PM
News IconAdamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Short Interest Decreased By 4.19% - Consumer Eagle (NASDAQ:ADMS)
www.consumereagle.com - July 16 at 3:18 PM
News IconEye on Stock Volatility for: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Engelwood Daily (NASDAQ:ADMS)
www.engelwooddaily.com - July 14 at 3:19 PM
capitalcube.com logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : July 13, 2016 (NASDAQ:ADMS)
www.capitalcube.com - July 13 at 8:04 AM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) Jumps 6.2% on July 12 - Equities.com (NASDAQ:ADMS)
www.equities.com - July 12 at 8:47 PM
investornewswire.com logoIs $45 Within Reach For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - July 8 at 8:30 PM
nasdaq.com logoWhy Adamas Pharmaceuticals (ADMS) Stock Might be a Great Pick - Nasdaq (NASDAQ:ADMS)
www.nasdaq.com - July 7 at 3:19 PM
finance.yahoo.com logoWhy Adamas Pharmaceuticals (ADMS) Stock Might be a Great Pick (NASDAQ:ADMS)
finance.yahoo.com - July 7 at 8:39 AM
News IconAdamas Pharmaceuticals Incorporated (NASDAQ:ADMS) Shorts Decreased by 4.19% After Short Covering - Press Telegraph (NASDAQ:ADMS)
presstelegraph.com - July 4 at 8:05 AM
capitalcube.com logoETF’s with exposure to Adamas Pharmaceuticals, Inc. : July 1, 2016 (NASDAQ:ADMS)
www.capitalcube.com - July 1 at 5:46 PM
ftsenews.co.uk logoAdamas Pharmaceuticals, Inc. (ADMS) Updated Price Targets - FTSE News (NASDAQ:ADMS)
www.ftsenews.co.uk - July 1 at 3:19 PM
News IconGreat Point Partners LLC Increased Adamas Pharmaceuticals INC (NASDAQ:ADMS) by $9.40 Million as Shares ... - Press Telegraph (NASDAQ:ADMS)
presstelegraph.com - July 1 at 11:16 AM
News IconUpdate on Stock Volatility for: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Engelwood Daily (NASDAQ:ADMS)
www.engelwooddaily.com - June 30 at 3:19 PM
publicnow.com logoAdamas Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference (NASDAQ:ADMS)
www.publicnow.com - June 29 at 4:31 PM
fiscalstandard.com logoBrokers Issue Average Price Target Of 33.78 On Adamas Pharmaceuticals, Inc. (ADMS) - Fiscal Standard (NASDAQ:ADMS)
www.fiscalstandard.com - June 29 at 3:16 PM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) Jumps 5.43% on June 28 - Equities.com (NASDAQ:ADMS)
www.equities.com - June 29 at 3:16 PM
thestreet.com logo16 Biopharma Companies Besides Medivation That Are Attractive Targets (NASDAQ:ADMS)
www.thestreet.com - June 29 at 1:28 PM
istreetwire.com logoStock Grabbing Investor's Attention: Adamas Pharmaceuticals, Inc. (ADMS) - iStreetWire (NASDAQ:ADMS)
istreetwire.com - June 25 at 3:19 PM
investornewswire.com logoStrong Sell Calls Recommendations For Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 0 - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - June 24 at 3:19 PM
insidermonkey.com logoTaking A Look At Adamas Pharmaceuticals Inc (ADMS)'s Upcoming Parkinson's NDA - Insider Monkey (blog) (NASDAQ:ADMS)
www.insidermonkey.com - June 24 at 11:27 AM
News IconTaking A Look At Adamas Pharmaceuticals Inc (ADMS)’s Upcoming Parkinson’s NDA (NASDAQ:ADMS)
feedproxy.google.com - June 23 at 1:10 PM
streetinsider.com logoAdamas Pharma (ADMS) Offers Additional Data from ADS-5102 Phase 3 in LID; Improvement in All Subgroups Noted (NASDAQ:ADMS)
www.streetinsider.com - June 23 at 11:03 AM
equities.com logoAdamas Pharmaceuticals Inc. (ADMS) Drops 7.97% on June 21 - Equities.com (NASDAQ:ADMS)
www.equities.com - June 22 at 8:30 PM

Social

Adamas Pharmaceuticals (NASDAQ:ADMS) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff